Sexually Transmitted Diseases

1
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Evofem Biosciences
Evofem BiosciencesCA - San Diego
1 program
1
EVO100Phase 31 trial
Active Trials
NCT04553068CompletedEst. Jul 2022
GS
Gilead SciencesFOSTER CITY, CA
2 programs
Pre Exposure ProphylaxisN/A1 trial
Pre Exposure ProphylaxisN/A
Active Trials
NCT02852226Completed30Est. Aug 2017
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
SexHealthN/A1 trial
Active Trials
NCT03341975CompletedEst. May 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Evofem BiosciencesEVO100
City TherapeuticsSexHealth
Gilead SciencesPre Exposure Prophylaxis

Clinical Trials (3)

Total enrollment: 30 patients across 3 trials

NCT04553068Evofem BiosciencesEVO100

Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection

Start: Oct 2020Est. completion: Jul 2022
Phase 3Completed
NCT03341975City TherapeuticsSexHealth

Enhanced SexHealth Intervention to Improve Adolescent Outcomes

Start: Dec 2017Est. completion: May 2020
N/ACompleted
NCT02852226Gilead SciencesPre Exposure Prophylaxis

CRUSH-PrEP for Women Project

Start: May 2016Est. completion: Aug 201730 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space